Zu den Inhalten springen
Marien Hospital Herne
St. Elisabeth Gruppe
Klinik für Urologie


Phase 2b Clinical Study Evaluating Efficacy and Safety of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With High-Risk Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guerin (BCG) Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy

© Marien Hospital Herne | Impressum | . Datenschutz | . Datenschutz­einstellungen anpassen.